<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Radiopharm Theranostics Ltd — News on 6ix</title>
    <link>https://6ix.com/company/radiopharm-theranostics-ltd</link>
    <description>Latest news and press releases for Radiopharm Theranostics Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 23 Apr 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/radiopharm-theranostics-ltd" rel="self" type="application/rss+xml" />
    <item>
      <title>Radiopharm Theranostics Reports Business Update</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-reports-business-update</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-reports-business-update</guid>
      <pubDate>Thu, 23 Apr 2026 11:00:00 GMT</pubDate>
      <description>Completed enrolment in Phase 2b clinical trial of imaging agent RAD 101 in patients with recurrent brain metastases following earlier announcement of interim data demonstrating concordance with MRI (the primary endpoint) in 90% of evaluable subjects (18/20) Presented initial Phase 0/1 data for RAD 202 at the American Association for Cancer Research demonstrating encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Received positive recommendation from Data and Safety</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Presents Initial Findings from Phase 1 First-in-Human HEAT Clinical Trial for 177Lu-RAD202 in HER2+ Solid Tumors at American Association for Cancer Research 2026</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-presents-initial-findings-from-phase-1-first-in-human-heat-clinical-trial-for-177lu-rad202-in-her2-solid-tumors-at-american-association-for-cancer-research-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-presents-initial-findings-from-phase-1-first-in-human-heat-clinical-trial-for-177lu-rad202-in-her2-solid-tumors-at-american-association-for-cancer-research-2026</guid>
      <pubDate>Mon, 20 Apr 2026 11:00:00 GMT</pubDate>
      <description>177Lu-RAD202 demonstrated encouraging tumor uptake and a favorable safety profile in the lowest dose cohort Data Safety and Monitoring Committee Recently Approved Advancing 177Lu-RAD202 to Next Highest Dose at 130 mCi SYDNEY, April 20, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announce</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Completes Enrollment in U.S. Phase 2b Imaging Trial of RAD 101 for Diagnosis of Brain Metastases</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-completes-enrollment-in-us-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-completes-enrollment-in-us-phase-2b-imaging-trial-of-rad-101-for-diagnosis-of-brain-metastases</guid>
      <pubDate>Thu, 16 Apr 2026 11:00:00 GMT</pubDate>
      <description>Interim data to date showed 90% concordance with MRI (the primary endpoint) Clinical trial readout (Primary endpoint) expected in June 2026 Plans to advance RAD 101 into U.S. Phase 3 pivotal trial SYDNEY, April 16, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical needs, today announced that the final patient has been d</description>
    </item>
    <item>
      <title>RAD Completes Enrollment in Phase 2b Trial of RAD 101</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-completes-enrollment-in-phase-2b-trial-of-rad-101</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-completes-enrollment-in-phase-2b-trial-of-rad-101</guid>
      <pubDate>Thu, 16 Apr 2026 03:02:04 GMT</pubDate>
      <description>RAD Completes Enrollment in Phase 2b Trial of RAD 101</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Advances to Cohort 3 in 177Lu-RAD202 Phase 1 Dose Escalating Clinical Trial</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-advances-to-cohort-3-in-177lu-rad202-phase-1-dose-escalating-clinical-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-advances-to-cohort-3-in-177lu-rad202-phase-1-dose-escalating-clinical-trial</guid>
      <pubDate>Wed, 08 Apr 2026 11:00:00 GMT</pubDate>
      <description>Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to progress Phase 1 to the next dose level of 130mCi in patients with HER2+ advanced solid tumorsSYDNEY, April 08, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that it has received a positive recom</description>
    </item>
    <item>
      <title>RAD202 Phase 1 HEAT Trial Advances to Dose Level 3</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad202-phase-1-heat-trial-advances-to-dose-level-3</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad202-phase-1-heat-trial-advances-to-dose-level-3</guid>
      <pubDate>Wed, 08 Apr 2026 03:21:05 GMT</pubDate>
      <description>RAD202 Phase 1 HEAT Trial Advances to Dose Level 3</description>
    </item>
    <item>
      <title>Radiopharm Theranostics and Siemens Healthineers Sign Clinical Supply Agreement for RAD101 in the U.S.</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-us</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-and-siemens-healthineers-sign-clinical-supply-agreement-for-rad101-in-the-us</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 GMT</pubDate>
      <description>Data from the interim analysis in Phase 2b trial of RAD101 showed significant and selective tumor uptake in brain metastases, with 90% concordance (Primary Endpoint) with MRI. Partnership ensures sufficient supply of RAD 101 in Phase 3 registrational trial in the U.S. SYDNEY, April 07, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of hig</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Doses First Patient in Phase 1 Clinical Study of RAD 402 in Advanced Prostate Cancer</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-doses-first-patient-in-phase-1-clinical-study-of-rad-402-in-advanced-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-doses-first-patient-in-phase-1-clinical-study-of-rad-402-in-advanced-prostate-cancer</guid>
      <pubDate>Fri, 27 Mar 2026 11:00:00 GMT</pubDate>
      <description>On track to share data from first two dose levels in 2H 2026 Targeting KLK3 and leveraging the dual emission of Tb161 represents an innovative approach for radiotherapies in Prostate Cancer Preclinical proof-of-concept mouse xenografts demonstrated RAD 402’s strong tumor targeting with minimal bone/marrow uptake and expected hepatic clearance SYDNEY, March 27, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company foc</description>
    </item>
    <item>
      <title>RAD Doses First Patient in RAD 402 Phase 1 Clinical Study</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-doses-first-patient-in-rad-402-phase-1-clinical-study</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-doses-first-patient-in-rad-402-phase-1-clinical-study</guid>
      <pubDate>Fri, 27 Mar 2026 01:45:07 GMT</pubDate>
      <description>RAD Doses First Patient in RAD 402 Phase 1 Clinical Study</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Achieves Primary Endpoint In 90% of Patients At Second Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-achieves-primary-endpoint-in-90percent-of-patients-at-second-interim-analysis-of-rad-101-phase-2b-imaging-trial-in-brain-metastases</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-achieves-primary-endpoint-in-90percent-of-patients-at-second-interim-analysis-of-rad-101-phase-2b-imaging-trial-in-brain-metastases</guid>
      <pubDate>Tue, 24 Mar 2026 11:00:00 GMT</pubDate>
      <description>90% of patients dosed with RAD 101 and evaluable at interim analysis achieved concordance with MRI imaging (the primary endpoint) First five patients with available data from six-month follow-up and biopsy show encouraging trend for Sensitivity and Specificity (secondary objective) Company to host webinar on March 25 at 9:00 am AEDT (Sydney, Melbourne) / Tuesday, March 24 at 6:00 pm EST (U.S.) SYDNEY, Australia, March 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX: RAD, “Radiopharm” o</description>
    </item>
    <item>
      <title>RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad101-2nd-interim-ph2b-data-90percent-achieve-primary-endpoint</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad101-2nd-interim-ph2b-data-90percent-achieve-primary-endpoint</guid>
      <pubDate>Tue, 24 Mar 2026 02:55:05 GMT</pubDate>
      <description>RAD101 2nd interim Ph.2b data - 90% achieve primary endpoint</description>
    </item>
    <item>
      <title>Half Year Report and Appendix 4D 31 December 2025</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/half-year-report-and-appendix-4d-31-december-2025-1</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/half-year-report-and-appendix-4d-31-december-2025-1</guid>
      <pubDate>Fri, 27 Feb 2026 07:24:11 GMT</pubDate>
      <description>Half Year Report and Appendix 4D 31 December 2025</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-doses-first-patient-in-phase-12a-clinical-study-of-betabart-rv-01</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-doses-first-patient-in-phase-12a-clinical-study-of-betabart-rv-01</guid>
      <pubDate>Tue, 24 Feb 2026 12:30:00 GMT</pubDate>
      <description>First radiotherapeutic agent developed by Radiopharm Ventures, the joint venture between Radiopharm Theranostics and MD Anderson Cancer Center Preclinical animal studies of BetaBart (RV-01) have demonstrated tumor shrinkage and prolonged survival SYDNEY, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, t</description>
    </item>
    <item>
      <title>RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-doses-first-patient-in-177lu-betabart-rv-01-study</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-doses-first-patient-in-177lu-betabart-rv-01-study</guid>
      <pubDate>Tue, 24 Feb 2026 03:46:06 GMT</pubDate>
      <description>RAD Doses First Patient in 177Lu-BetaBart (RV-01) Study</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-reports-half-year-financial-results-and-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-reports-half-year-financial-results-and-business-updates</guid>
      <pubDate>Wed, 28 Jan 2026 12:00:00 GMT</pubDate>
      <description>Interim results from Phase 2b clinical trial of RAD 101 showed 92% of evaluable participants met the primary endpoint of MRI concordance in imaging study of patients with brain metastases Interim data from additional Cohorts of the Phase 1 clinical trial of RAD 202 and RAD 204 in advanced solid tumors are expected in mid-2026 Cash and cash equivalents of approximately $34.52 million provide runway into 2027 to advance pipeline of high value radiotherapeutic programs through key clinical and regu</description>
    </item>
    <item>
      <title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-66</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/quarterly-activitiesappendix-4c-cash-flow-report-66</guid>
      <pubDate>Wed, 28 Jan 2026 03:39:19 GMT</pubDate>
      <description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
    </item>
    <item>
      <title>Presenting on Emerging Growth Conference 89 Day 2 on January 22; Register to live stream</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/presenting-on-emerging-growth-conference-89-day-2-on-january-22-register-to-live-stream-4</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/presenting-on-emerging-growth-conference-89-day-2-on-january-22-register-to-live-stream-4</guid>
      <pubDate>Wed, 21 Jan 2026 12:00:00 GMT</pubDate>
      <description>MIAMI, Jan. 21, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of Day 2 of the 89th Emerging Growth Conference on January 21 &amp; 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products &amp; services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presen</description>
    </item>
    <item>
      <title>Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/presenting-on-emerging-growth-conference-89-day-1-on-january-21-register-to-live-stream-2</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/presenting-on-emerging-growth-conference-89-day-1-on-january-21-register-to-live-stream-2</guid>
      <pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
      <description>MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 89th Emerging Growth Conference on January 21 &amp; 22, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products &amp; services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting comp</description>
    </item>
    <item>
      <title>RAD Increases Ownership in Radiopharm Ventures to 87.5%</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-increases-ownership-in-radiopharm-ventures-to-875percent</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/rad-increases-ownership-in-radiopharm-ventures-to-875percent</guid>
      <pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
      <description>Radiopharm Ventures, LLC, is a joint venture created in 2022 between MD Anderson Cancer Center and Radiopharm TheranosticsLeading candidate Betabart, a monoclonal antibody targeting B7H3, has received FDA IND clearance for a Phase I therapeutic trial in multiple solid tumors expected to dose the first patient in Q1 2026 First clinical trial globally targeting B7H3 with a systemic radiopharmaceuticalTwo additional preclinical Radiopharm Ventures’ assets show early positive results with plans to m</description>
    </item>
    <item>
      <title>Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases</title>
      <link>https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-achieves-primary-endpoint-in-92percent-of-patients-at-interim-analysis-of-rad-101-phase-2b-imaging-trial-in-brain-metastases</link>
      <guid isPermaLink="true">https://6ix.com/company/radiopharm-theranostics-ltd/news/radiopharm-theranostics-achieves-primary-endpoint-in-92percent-of-patients-at-interim-analysis-of-rad-101-phase-2b-imaging-trial-in-brain-metastases</guid>
      <pubDate>Mon, 15 Dec 2025 12:00:00 GMT</pubDate>
      <description>92% of evaluable patients at interim analysis treated with RAD 101 achieved concordance¹ with MRI imaging (the primary endpoint) with significant and selective tumor uptake in suspected or recurrent brain metastases Company to host webinar on Tuesday, December 16 at 10:00 am AEDT (Australia) / Monday, December 15 at 6:00 pm EST (U.S.) SYDNEY, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on d</description>
    </item>
  </channel>
</rss>